Market Pathways Scorecard: PCCPs at FDA, 2025 Edition
A infographic look at FDA's use of Predetermined Change Control Plans.
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
A infographic look at FDA's use of Predetermined Change Control Plans.
Now that Sensome has advanced its ultra-miniaturized in situ tissue characterization platform in stroke, it’s heading for the lung cancer market, where it has the potential to increase the diagnostic yield of bronchoscopic biopsies.
Determining the value of healthcare data is an emerging field that comes with industry-specific legal and logistical challenges. Excerpted from our recent feature article, “Data Is the New Gold.”